• 1
    Report to the President and the Congress on Comparative Effectiveness Research, US Department of Health and Human Services,, accessed July 15, 2011.
  • 2
    Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997; 50: 683691.
  • 3
    Eckert L, Falissard B. Using meta-regression in performing indirect-comparisons: comparing escitalopram with venlafaxine XR. Curr Med Res Opin 2006; 22(11): 23132321.
  • 4
    Nixon RM, Bansback N, Brennan A. Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. Stat Med 2007; 26: 12371254.
  • 5
    Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess 2005; 9(26): 1134.
  • 6
    Sutton A, Ades AE, Cooper N, et al. Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics 2008; 26: 753767.
  • 7
    Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med 2002; 21: 23132324.
  • 8
    Hoaglin DC, Hawkins N, Jansen JP, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR task force on indirect treatment comparisons good research practices-part 2. Value Health 2011 Jun; 14(4): 429437.
  • 9
    Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1. Value Health 2011 Jun; 14(4): 417428.
  • 10
    Wells GA, Sultan SA, Chen L, et al. Indirect Evidence: Indirect Treatment Comparisons in Meta-Analysis. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2009.
  • 11
    NICE Guide to the Methods of Technology Appraisal,
  • 12
    Phillips A. 2003 Trial and error: cross-trial comparisons of antiretroviral regimens. AIDS 2003; 17: 619623.
  • 13
    Cranney A, Guyatt G, Griffith L, et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23(4): 570578.
  • 14
    Deeks JJ, Higgins JPT, Altman DG, editors. Analysing and presenting results. In Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6; Section 8. In: The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & Sons, Ltd.
  • 15
    Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992; 327: 16181624.
  • 16
    Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ 1998; 316: 894898.
  • 17
    Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer; a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899909.
  • 18
    Moore RA, McQuay HJ. Single-patient data metaanalysis of 3453 postoperative patients: oral tramadol versus placebo, codeine and combination analgesics. Pain 1997; 69: 287294.
  • 19
    Turner RM, Omar RZ, Yang M, et al. A multilevel model framework for meta-analysis of clinical trials with binary outcomes. Stat Med 2000; 19: 34173432.
  • 20
    Neumann PJ, Drummond MF, Jönsson B, et al. Are key principles for improved health technology assessment supported and used by health technology assessment organizations? Int J Technol Assess Health Care 2010; 26: 1: 7178.
  • 21
    Ross SD. Trends in meta-analysis. Drug Inf J 2009; 43: 171176.
  • 22
    Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics 2010; 28(10): 935945
  • 23
    National Health Interview Survey. Hyattsville, MD.: National Center for Health Statistics; 2009. Available at accessed on 06/08/11
  • 24
    National Collaborating Centre for Mental Health. Attention Deficit Hyperactivity Disorder: Diagnosis and management of ADHD in children, young people and adults. National Clinical Practice Guideline Number 72, March 2009.
  • 25
    Pliszka SR, Crismon ML, Hughes CW, et al. Texas consensus conference panel on pharmacotherapy of childhood attention deficit hyperactivity disorder. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006 Jun; 45(6): 642657.
  • 26
    American Academy of Pediatrics. Subcommittee on attention-deficit/hyperactivity disorder and committee on quality improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 2001 Oct; 108(4): 10331044.
  • 27
    Findling RL. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review. Clin Ther 2008 May; 30(5): 942957.
  • 28
    Wilens TE. Update on attention deficit hyperactivity disorder, I. Curr Affect Illness. 1996; 15: 512.
  • 29
    Connor DF, Findling RL, Kollins SH, et al. Effects of guanfacine extended release on oppositional symptoms in children aged 6–12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. CNS Drugs 2010 Sep 1; 24(9): 755768.
  • 30
    Kaplan S, Heiligenstein J, West S, et al. Efficacy and safety of Atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder. J Atten Disord 2004 Oct; 8(2): 4552.
  • 31
    Dell'Agnello G, Maschietto D, et al. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a placebo-controlled Italian study. Eur Neuropsychopharmacol 2009 Nov; 19(11): 822834.
  • 32
    Newcorn JH, Spencer TJ, Biederman J, et al. Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry 2005 Mar; 44(3): 240248.
  • 33
    Bangs ME, Hazell P, Danckaerts M, et al. Atomoxetine ADHD/ODD study group. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder. Pediatrics 2008 Feb; 121(2): e314e320.
  • 34
    Hazell P, Becker K, Nikkanen EA, et al. Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. Atten Defic Hyperact Disord. 2009 Dec;1(2):201210.
  • 35
    Hazell P, Zhang S, Wolanczyk T, et al. Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry 2006 Mar; 15(2): 105110.
  • 36
    Conners CK, Sitarenios G, Parker JD, et al. The Revised Conners' Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol 1998; 26(4): 257268.
  • 37
    DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD Rating Scale-IV:Checklists, Norms, and Clinical Interpretations. New York, NY: The Guilford Press, 1998.
  • 38
    Casella G, Berger RL. 2002. Statistical Inference. Duxbury, Thomson Learning, Pacific Grove, CA, 2002.